Table 11

Pegaptanib safety

Cunningham et al / Adamis et al3957Sultan et al40
Number of patientsIVP0.3, n=44 eyes; IVP1, n=44 eyes; IVP3, n=42 eyesIVP, n=133 eyes; C, n=127 eyes
Ocular adverse events
 Eye painPegaptanib: 31%; C: 17%IVP: 11.1%; C: 7%
 Vitreous haemorrhagePegaptanib: 22%; C: 7%IVP: 6.3%; C: 7.7%
 Punctuate keratitisPegaptanib: 18%; C: 17%IVP: 11.8%; C: 6.3%
 CataractPegaptanib: 13%; C: 10%IVP: 8.3%; C: 9.2%
 Eye dischargePegaptanib: 11%; C: 10%NR
 Conjunctival haemorrhagePegaptanib: 10%; C: 0%IVP: 22.2%; C: 14.1%
 Vitreous opacitiesPegaptanib: 9%; C: 5%NR
 Blurred visionPegaptanib: 7%; C: 5%NR
 Other vitreous disorderPegaptanib: 7%; C: 0%NR
 Other visual disturbancePegaptanib: 7%; C: 0%NR
 Culture-negative endophthalmitisPegaptanib: n=1NR
 IOP increaseNRIVP: 17.4%; C: 6.3%
 Retinal haemorrhageNRIVP: 6.3%; C: 10.6%
 Retinal exudatesNRIVP: 6.3%; C: 5.6%
 ConjunctivitisNRIVP: 5.6%; C: 4.2%
 Lacrimation increasedNRIVP: 5.6%; C: 2.8%
 Diabetic retinal oedemaNRIVP: 11.1%; C: 17.6%
 Macular oedemaNRIVP: 9.7%; C: 11.6%
Systemic adverse events
 Non-ocular hypertensionNRIVP: 13.9%; C: 9.9%
 Cardiac disordersNRIVP: 6.9%; C: 5.6%
DeathsNRIVP: n=4
  • IOP, intraocular pressure; IVP, intravitreal pegaptanib; NR, not reported.